Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M, Chiba T, Zen Y, Oshima M, Kusakabe Y, Noguchi Y, Yuki K, Koide S, Tara S, Saraya A, Aoyama K, Mimura N, Miyagi S, Inoue M, Wakamatsu T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Otsuka M, Miyazaki M, Yokosuka O, Iwama A. Yokoyama M, et al. Among authors: mimura n. Oncotarget. 2017 Mar 28;8(13):21315-21326. doi: 10.18632/oncotarget.15528. Oncotarget. 2017. PMID: 28423509 Free PMC article.
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T, Ma A, Jin J, Iseki T, Nakaseko C, Iwama A. Rizq O, et al. Among authors: mimura n. Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. doi: 10.1158/1078-0432.CCR-16-2735. Epub 2017 May 10. Clin Cancer Res. 2017. PMID: 28490465 Free PMC article.
Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells.
Kanayama K, Chiba T, Oshima M, Kanzaki H, Koide S, Saraya A, Miyagi S, Mimura N, Kusakabe Y, Saito T, Ogasawara S, Suzuki E, Ooka Y, Maruyama H, Iwama A, Kato N. Kanayama K, et al. Among authors: mimura n. Stem Cells Int. 2019 Apr 1;2019:9789240. doi: 10.1155/2019/9789240. eCollection 2019. Stem Cells Int. 2019. PMID: 31065285 Free PMC article.
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Kanzaki H, Chiba T, Ao J, Koroki K, Kanayama K, Maruta S, Maeda T, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Mimura N, Kato J, Zen Y, Ohtsuka M, Iwama A, Kato N. Kanzaki H, et al. Among authors: mimura n. Sci Rep. 2021 Mar 5;11(1):5303. doi: 10.1038/s41598-021-84117-9. Sci Rep. 2021. PMID: 33674622 Free PMC article.
Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
Ao J, Chiba T, Shibata S, Kurosugi A, Qiang N, Ma Y, Kan M, Iwanaga T, Sakuma T, Kanzaki H, Kanayama K, Kojima R, Kusakabe Y, Nakamura M, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Muroyama R, Kato J, Mimura N, Kanda T, Maruyama H, Kato N. Ao J, et al. Among authors: mimura n. Biochem Biophys Res Commun. 2021 Apr 16;549:171-178. doi: 10.1016/j.bbrc.2021.02.097. Epub 2021 Mar 3. Biochem Biophys Res Commun. 2021. PMID: 33676186
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y, Chiba T, Oshima M, Koide S, Rizq O, Aoyama K, Ao J, Kaneko T, Kanzaki H, Kanayama K, Maeda T, Saito T, Nakagawa R, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Nakamoto S, Yasui S, Mikata R, Muroyama R, Kanda T, Maruyama H, Kato J, Mimura N, Ma A, Jin J, Zen Y, Otsuka M, Kaneda A, Iwama A, Kato N. Kusakabe Y, et al. Among authors: mimura n. Sci Rep. 2021 Nov 1;11(1):21396. doi: 10.1038/s41598-021-00889-0. Sci Rep. 2021. PMID: 34725436 Free PMC article.
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, Saraya A, Koide S, Nakajima-Takagi Y, Miyota M, Chiba T, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Nakaseko C, Lennox W, Sheedy J, Weetall M, Yokote K, Iwama A, Sakaida E. Nagai Y, et al. Among authors: mimura n. Sci Rep. 2021 Jan 22;11(1):2074. doi: 10.1038/s41598-021-81577-x. Sci Rep. 2021. PMID: 33483574 Free PMC article.
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience.
Ogawa K, Kanzaki H, Chiba T, Ao J, Qiang N, Ma Y, Zhang J, Yumita S, Ishino T, Unozawa H, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Kanda T, Maruyama H, Mimura N, Kato J, Motohashi S, Kato N. Ogawa K, et al. Among authors: mimura n. J Cancer. 2022 May 16;13(8):2656-2661. doi: 10.7150/jca.71494. eCollection 2022. J Cancer. 2022. PMID: 35711837 Free PMC article.
Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.
Shimizu R, Muto T, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri-Manako C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Iseki T, Starczynowski DT, Iwama A, Yokote K, Nakaseko C. Shimizu R, et al. Among authors: mimura n. Leuk Res. 2016 Nov;50:85-94. doi: 10.1016/j.leukres.2016.09.018. Epub 2016 Sep 26. Leuk Res. 2016. PMID: 27697661 Free PMC article.
256 results